Day 1 Recap
With faculty who specialize in everything from acne, atopic dermatitis (AD), and psoriasis to skin cancers, surgical pearls, and nonsurgical facial rejuvenation, Hawaii Derm brings you the latest dermatological advancements—with presentations that define the latest proven breakthrough treatments for your hardest patient cases. A robust and comprehensive agenda targets all new developments in medical and aesthetic medicine and the treatment of skin diseases, this 5-day event covers all of your CME needs in one meeting.
The Hawaii Derm agenda is quite comprehensive! It covers acne and rosacea, skin cancers, psoriasis and atopic dermatitis, pediatric dermatology and aesthetics, and so much more. I am always motivated and excited to hear about new drugs and what is coming down the pipeline to help my patients.
— Julie Harper, MD
The faculty assembled for Hawaii Derm is superb, representing some of the most famous names in medical and pediatric dermatology—such as Jeff Callen and Amy Paller—leaders who write our standard textbooks and advance the field, while also being expert clinicians and fabulous speakers.
— Dr. Lawrence Eichenfield
One aspect of my talks that is critical is on JAK inhibitors—they are such an important item in our treatment toolbox for AD patients. Novel data continues to be released highlighting their safety and efficacy, so in Session 3 today I shared updated safety data on the systemic JAK inhibitors.
— Dr. Yu
Presenter Andrew Alexis, MD, mentioned one of the most anticipated AD sessions: “I especially appreciated All You Need to Know About Atopic Dermatitis and Then Some—the two-part session led by renowned expert, Melinda Gooderham, with an amazing lineup of speakers covering the latest updates and best practices for treating our patients with AD!”
So what else was not to be missed on Day 1 of Hawaii Derm?
- Updates on Topical Agents in the AD Toolbox—Tina Bhutani, MD
- Biologics for Atopic Dermatitis: What’s New—Melinda J. Gooderham, MD
- JAK Inhibitors for Atopic Dermatitis: What You Need to Know Now—JiaDe Yu, MD
- Looking Ahead at the Atopic Dermatitis Pipeline—Melinda J. Gooderham, MD
- Connective Tissue Diseases in Dermatology—Jeffrey P. Callen, MD
- What’s New in Acne—Andrew F. Alexis, MD
- Approaches to Allergy in Atopic Dermatitis—Bob Geng, MD
Today Session 3 also showcased Drs. Eichenfield and Sean Kwatra presenting, Is Your Patient a Candidate for Systemic Treatment? “We used cases to discuss the practical aspects of deciding when it’s time to escalate treatment, especially in the challenging situation of very young patients,” shared Dr. Eichenfield. “While a pearl there is “It’s always patient and family by patient and family,” we illustrated standard approaches of assessing both disease severity as well as when the patient and family is “ready” to make the move.
With faculty who specialize in everything from acne, atopic dermatitis (AD), and psoriasis to skin cancers, surgical pearls, and nonsurgical facial rejuvenation, Hawaii Derm brings you the latest dermatological advancements—with presentations that define the latest proven breakthrough treatments for your hardest patient cases. A robust and comprehensive agenda targets all new developments in medical and aesthetic medicine and the treatment of skin diseases, this 5-day event covers all of your CME needs in one meeting.
The Hawaii Derm agenda is quite comprehensive! It covers acne and rosacea, skin cancers, psoriasis and atopic dermatitis, pediatric dermatology and aesthetics, and so much more. I am always motivated and excited to hear about new drugs and what is coming down the pipeline to help my patients.
— Julie Harper, MD
The faculty assembled for Hawaii Derm is superb, representing some of the most famous names in medical and pediatric dermatology—such as Jeff Callen and Amy Paller—leaders who write our standard textbooks and advance the field, while also being expert clinicians and fabulous speakers.
— Dr. Lawrence Eichenfield
One aspect of my talks that is critical is on JAK inhibitors—they are such an important item in our treatment toolbox for AD patients. Novel data continues to be released highlighting their safety and efficacy, so in Session 3 today I shared updated safety data on the systemic JAK inhibitors.
— Dr. Yu
Presenter Andrew Alexis, MD, mentioned one of the most anticipated AD sessions: “I especially appreciated All You Need to Know About Atopic Dermatitis and Then Some—the two-part session led by renowned expert, Melinda Gooderham, with an amazing lineup of speakers covering the latest updates and best practices for treating our patients with AD!”
So what else was not to be missed on Day 1 of Hawaii Derm?
- Updates on Topical Agents in the AD Toolbox—Tina Bhutani, MD
- Biologics for Atopic Dermatitis: What’s New—Melinda J. Gooderham, MD
- JAK Inhibitors for Atopic Dermatitis: What You Need to Know Now—JiaDe Yu, MD
- Looking Ahead at the Atopic Dermatitis Pipeline—Melinda J. Gooderham, MD
- Connective Tissue Diseases in Dermatology—Jeffrey P. Callen, MD
- What’s New in Acne—Andrew F. Alexis, MD
- Approaches to Allergy in Atopic Dermatitis—Bob Geng, MD
Today Session 3 also showcased Drs. Eichenfield and Sean Kwatra presenting, Is Your Patient a Candidate for Systemic Treatment? “We used cases to discuss the practical aspects of deciding when it’s time to escalate treatment, especially in the challenging situation of very young patients,” shared Dr. Eichenfield. “While a pearl there is “It’s always patient and family by patient and family,” we illustrated standard approaches of assessing both disease severity as well as when the patient and family is “ready” to make the move.
